Blood cancer patients with Covid have a higher risk of serious illness


AstraZeneca has launched a phase 1 clinical trial of its drug AZD7442, a combination of two monoclonal antibodies, for the prevention and treatment of Covid-19.The trial will assess the safety, tolerability and pharmacokinetics of the drug and will include up to 48 healthy UK participants aged 18 to 55.

It is funded by the Defense Advanced Research Projects Agency (DARPA), which is part of the US Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response in the USA. Department of Health and Human Services.

Mene Pangalos, Executive Vice President, R&D BioPharmaceuticals, said: ‚ÄúThis trial is an important step in the development of our combination of monoclonal antibodies to prevent or treat COVID-19. This combination of antibodies, together with our proprietary half-life extension technology, has the potential to improve both efficacy and durability of use in addition to reducing the likelihood of viral resistance. ”

If AZD7442 is found to be tolerated and has a favorable safety profile in the trial, AstraZeneca will progress it to larger phase II and late stage phase III trials to assess its efficacy as a preventive approach. and potential therapeutic against COVID-19.


Please enter your comment!
Please enter your name here